vs
LivaNova PLC（LIVN）とUiPath, Inc.（PATH）の財務データ比較。上の社名をクリックして会社を切り替えられます
UiPath, Inc.の直近四半期売上が大きい（$411.1M vs $360.9M、LivaNova PLCの約1.1倍）。UiPath, Inc.の純利益率が高く（48.4% vs 8.6%、差は39.8%）。UiPath, Inc.の前年同期比売上増加率が高い（15.9% vs 12.1%）。LivaNova PLCの直近四半期フリーキャッシュフローが多い（$50.2M vs $25.1M）。過去8四半期でLivaNova PLCの売上複合成長率が高い（10.6% vs 0.7%）
LivaNova PLCは医療機器メーカーで、イギリスに本社を置いています。心臓外科手術用機器と神経調整用機器の開発を主な事業とし、2015年に米国のサイバロニクス社とイタリアのソリン社が27億米ドルで合併して設立されました。現在はNASDAQに上場し、証券コードはLIVNです。
UiPath Inc.は人工知能（AI）、自律型オートメーションおよびオーケストレーションソフトウェアを開発するグローバルソフトウェア企業です。同社の製品は複雑な業務プロセスやワークフローを自動化するAIエージェントの構築・管理に対応し、各業界の業務効率向上を支援しています。
LIVN vs PATH — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $360.9M | $411.1M |
| 純利益 | $30.9M | $198.8M |
| 粗利率 | 65.2% | 83.3% |
| 営業利益率 | 11.8% | 3.2% |
| 純利益率 | 8.6% | 48.4% |
| 売上前年比 | 12.1% | 15.9% |
| 純利益前年比 | -44.7% | 1966.2% |
| EPS（希薄化後） | $0.57 | $0.37 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $360.9M | $411.1M | ||
| Q3 25 | $357.8M | $361.7M | ||
| Q2 25 | $352.5M | $356.6M | ||
| Q1 25 | $316.9M | $423.6M | ||
| Q4 24 | $321.8M | $354.7M | ||
| Q3 24 | $318.1M | $316.3M | ||
| Q2 24 | $318.6M | $335.1M | ||
| Q1 24 | $294.9M | $405.3M |
| Q4 25 | $30.9M | $198.8M | ||
| Q3 25 | $26.8M | $1.6M | ||
| Q2 25 | $27.2M | $-22.6M | ||
| Q1 25 | $-327.3M | $51.8M | ||
| Q4 24 | $55.9M | $-10.7M | ||
| Q3 24 | $33.0M | $-86.1M | ||
| Q2 24 | $16.3M | $-28.7M | ||
| Q1 24 | $-41.9M | $33.9M |
| Q4 25 | 65.2% | 83.3% | ||
| Q3 25 | 68.4% | 82.2% | ||
| Q2 25 | 67.8% | 82.1% | ||
| Q1 25 | 69.7% | 84.8% | ||
| Q4 24 | 68.2% | 82.0% | ||
| Q3 24 | 70.8% | 80.0% | ||
| Q2 24 | 68.7% | 83.5% | ||
| Q1 24 | 70.3% | 86.8% |
| Q4 25 | 11.8% | 3.2% | ||
| Q3 25 | 15.1% | -5.6% | ||
| Q2 25 | 15.4% | -4.6% | ||
| Q1 25 | 15.3% | 7.9% | ||
| Q4 24 | 11.5% | -12.2% | ||
| Q3 24 | 11.2% | -32.7% | ||
| Q2 24 | 12.6% | -14.8% | ||
| Q1 24 | 5.5% | 3.7% |
| Q4 25 | 8.6% | 48.4% | ||
| Q3 25 | 7.5% | 0.4% | ||
| Q2 25 | 7.7% | -6.3% | ||
| Q1 25 | -103.3% | 12.2% | ||
| Q4 24 | 17.4% | -3.0% | ||
| Q3 24 | 10.4% | -27.2% | ||
| Q2 24 | 5.1% | -8.6% | ||
| Q1 24 | -14.2% | 8.4% |
| Q4 25 | $0.57 | $0.37 | ||
| Q3 25 | $0.49 | $0.00 | ||
| Q2 25 | $0.50 | $-0.04 | ||
| Q1 25 | $-6.01 | $0.09 | ||
| Q4 24 | $1.04 | $-0.02 | ||
| Q3 24 | $0.60 | $-0.15 | ||
| Q2 24 | $0.30 | $-0.05 | ||
| Q1 24 | $-0.78 | $0.07 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $635.6M | $1.4B |
| 総負債低いほど良い | $376.1M | — |
| 株主資本純資産 | $1.2B | $1.9B |
| 総資産 | $2.6B | $2.9B |
| 負債/資本比率低いほどレバレッジが低い | 0.31× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $635.6M | $1.4B | ||
| Q3 25 | $646.1M | $1.4B | ||
| Q2 25 | $593.6M | $1.6B | ||
| Q1 25 | $738.4M | $1.6B | ||
| Q4 24 | $428.9M | $1.6B | ||
| Q3 24 | $346.4M | $1.7B | ||
| Q2 24 | $329.2M | $1.9B | ||
| Q1 24 | $309.2M | $1.9B |
| Q4 25 | $376.1M | — | ||
| Q3 25 | $434.5M | — | ||
| Q2 25 | $430.6M | — | ||
| Q1 25 | $628.2M | — | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — | ||
| Q1 24 | $623.8M | — |
| Q4 25 | $1.2B | $1.9B | ||
| Q3 25 | $1.2B | $1.7B | ||
| Q2 25 | $1.1B | $1.7B | ||
| Q1 25 | $1.0B | $1.8B | ||
| Q4 24 | $1.3B | $1.7B | ||
| Q3 24 | $1.3B | $1.8B | ||
| Q2 24 | $1.2B | $2.0B | ||
| Q1 24 | $1.2B | $2.0B |
| Q4 25 | $2.6B | $2.9B | ||
| Q3 25 | $2.6B | $2.6B | ||
| Q2 25 | $2.5B | $2.6B | ||
| Q1 25 | $2.6B | $2.9B | ||
| Q4 24 | $2.5B | $2.7B | ||
| Q3 24 | $2.5B | $2.7B | ||
| Q2 24 | $2.5B | $2.8B | ||
| Q1 24 | $2.5B | $3.0B |
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.51× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $82.4M | $28.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $50.2M | $25.1M |
| FCFマージンFCF / 売上 | 13.9% | 6.1% |
| 設備投資強度設備投資 / 売上 | 8.9% | 0.8% |
| キャッシュ転換率営業CF / 純利益 | 2.67× | 0.14× |
| 直近12ヶ月FCF直近4四半期 | $173.3M | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $82.4M | $28.3M | ||
| Q3 25 | $85.1M | $41.6M | ||
| Q2 25 | $62.9M | $119.0M | ||
| Q1 25 | $24.0M | $146.1M | ||
| Q4 24 | $78.7M | $28.1M | ||
| Q3 24 | $51.0M | $46.4M | ||
| Q2 24 | $43.4M | $100.0M | ||
| Q1 24 | $10.0M | $145.6M |
| Q4 25 | $50.2M | $25.1M | ||
| Q3 25 | $62.2M | — | ||
| Q2 25 | $47.8M | $106.2M | ||
| Q1 25 | $13.2M | $138.7M | ||
| Q4 24 | $68.3M | $23.2M | ||
| Q3 24 | $32.8M | $45.0M | ||
| Q2 24 | $31.2M | $98.8M | ||
| Q1 24 | $3.6M | $141.8M |
| Q4 25 | 13.9% | 6.1% | ||
| Q3 25 | 17.4% | — | ||
| Q2 25 | 13.6% | 29.8% | ||
| Q1 25 | 4.2% | 32.7% | ||
| Q4 24 | 21.2% | 6.5% | ||
| Q3 24 | 10.3% | 14.2% | ||
| Q2 24 | 9.8% | 29.5% | ||
| Q1 24 | 1.2% | 35.0% |
| Q4 25 | 8.9% | 0.8% | ||
| Q3 25 | 6.4% | 0.0% | ||
| Q2 25 | 4.3% | 3.6% | ||
| Q1 25 | 3.4% | 1.7% | ||
| Q4 24 | 3.2% | 1.4% | ||
| Q3 24 | 5.7% | 0.4% | ||
| Q2 24 | 3.8% | 0.4% | ||
| Q1 24 | 2.2% | 0.9% |
| Q4 25 | 2.67× | 0.14× | ||
| Q3 25 | 3.18× | 26.25× | ||
| Q2 25 | 2.32× | — | ||
| Q1 25 | — | 2.82× | ||
| Q4 24 | 1.41× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 2.65× | — | ||
| Q1 24 | — | 4.29× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
